Research Paper Volume 16, Issue 2 pp 1440—1462
Identification and validation of SLCO4C1 as a biological marker in hepatocellular carcinoma based on anoikis classification features
Figure 6. Immunotherapy response in different risk groups. (A–E) Expression of the 5 immune checkpoint genes in the risk groups. (F–I) IPS in the four immunotherapy groups in the risk groups. (J) Statistics of the treatment degree of patients in IMvigor210 cohort. (K–M) TIDE scores were calculated for immunotherapy responsiveness in the risk groups.